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Abstract 
Background: Malaria in pregnancy is a major public health problem in Uganda; and it is the leading cause of anae-
mia among pregnant women and low birth weight in infants. Previous studies have noted poor quality of care in 
the private sector. Thus there is need to explore ways of improving quality of care in the private sector that provides 
almost a half of health services in Uganda.
Methods: A survey was conducted from August to October 2014 within 57 parishes in Mukono district, central 
Uganda. The selected parishes had a minimum of 200 households and at least one registered drug shop, pharmacy 
or private clinic. Data was collected using a structured questionnaire targeting one provider who was found on duty 
in each selected private health facility and consented to the study. The main variables were: provider characteristics, 
previous training received, type of drugs stocked, treatment and prevention practices for malaria among pregnant 
women. The main study outcome was the proportion of private health facilities who prescribe treatment of fever 
among pregnant women as recommended in the guidelines.
Results: A total of 241 private health facilities were surveyed; 70.5 % were registered drug shops, 24.5 % private 
clinics and 5.0 % pharmacies. Treatment of fever among pregnant women in accordance with the national treat-
ment guidelines was poor: 40.7 % in private clinics, decreasing to 28.2 % in drug shops and 16.7 % at pharmacies. 
Anti-malarial monotherapies sulphadoxine-pyrimethamine and quinine were commonly prescribed, often without 
consideration of gestational age. The majority of providers (>75 %) at all private facilities prescribed SP for intermittent 
preventive treatment but artemisinin-based combination therapy was prescribed: 8.3, 6.9 and 8.3 % respectively at 
drug shops, private clinics and pharmacies for prevention of malaria in pregnancy. Few facilities had malaria treatment 
guidelines; (44.1 % of private clinics, 17.9 % of drug shops, and 41.7 % at pharmacies. Knowledge of people at risk of 
malaria, P = 0.02 and availability of malaria treatment guidelines, P = 0.03 were the factors that most influenced cor-
rect treatment of fever in pregnancy.
Conclusion: Treatment of fever during pregnancy was poor in this study setting. These data highlight the need to 
develop interventions to improve patient safety and quality of care for pregnant women in the private health sector 
in Uganda.
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Background
Malaria in pregnancy is a major public health problem 
in Uganda [1], responsible for anaemia among pregnant 
women and low birth weight in infants [2]. The current 
policy for treating malaria in pregnancy in the first tri-
mester is to give quinine 10  m/kg; and during the sec-
ond and third trimester, artemisinin-based combination 
therapy (ACT) is recommended. For malaria prevention 
in Uganda, the policy recommends at least three doses of 
sulfadoxine-pyrimethamine (SP) as intermittent preven-
tive treatment (IPTp), and use of insecticide-treated bed 
nets (ITNs) [3]. Adherence to the guidelines (not to give 
ACT or any anti-malarial monotherapies during the first 
trimester) would ensure effective treatment of malaria 
and patient safety.
Although utilization of health-facility based inter-
ventions like antenatal care (ANC) and delivery care 
is generally poor [4], SP-IPTp has one of the lowest 
implementation rates compared to other interven-
tions in pregnancy and childhood. Recent data shows 
that low utilization of essential health services leads 
to missed opportunity. For example, 47.6  % pregnant 
women attend the required four antenatal care visits; 
26.7  % receive the two doses of SP-IPTp while 55.5  % 
get at least two doses of tetanus toxic vaccination [4]. 
Previous studies have assessed factors associated with 
low utilization of health-based interventions, including 
maternity services, and have documented socio-cultural 
factors, economic, constraints, negative perceptions, 
poor quality of care and long distances to health units 
[5–14].
Several studies have implemented private-sector inter-
ventions aimed at increasing access to malaria prevention 
services in Uganda. One study implemented at a com-
munity level, assessed whether drug shops, traditional 
birth attendants, community health workers and peer 
adolescent mobilizers would increases access to essential 
maternity services. The study demonstrated increased 
access to two doses of SP with an impact on pregnancy 
outcomes [15, 16]. It was further shown that the dis-
tribution of SP at a community level did not negatively 
affect access to essential health services at health facili-
ties [2]. Another study assessed the feasibility of private 
midwives in prevention of mother-to-child transmission 
of human immune deficiency virus (HIV) [17]. The study 
showed that private midwives were already providing 
essential maternity services; and they were trusted by 
their communities. Despite this scenario, access to HIV 
and malaria preventive services was low among the poor, 
the young and the less educated women. Following this 
study, it was recommended that private midwives be 
given refresher courses, to improve the quality of services 
[17].
It has also been shown that many patients (includ-
ing pregnant women) with febrile illnesses receive anti-
malarial drugs and only 34 % of malaria patients received 
an appropriate ACT regimen. This practice is due to the 
continued practice of presumptive treatment, inadequate 
training on malaria management and lack of knowledge 
that artemether-lumefantrine (Coartem®) was the rec-
ommended first-line treatment for malaria in Uganda 
[18].
Based on the above evidence, and the need to scale up 
services to achieve universal coverage, Uganda formu-
lated a public–private partnership policy and is currently 
discussing modalities for its implementation [1]. Stud-
ies to guide this process are required, including explor-
ing the feasibility of involving the private health sector in 
prevention and control of malaria in pregnancy. The main 
objective of the study was to assess quality of care in the 
private sector for patients seeking care in this outlet [19]. 
Specifically the sub-study assessed existing malaria pre-
vention and treatment practices in the private sector in 
order to design effective interventions to improve access 
and quality of care for pregnant women seeking treat-
ment in this sector.
Methods
Study design and setting
The study design is reported elsewhere [19], but briefly 
the study was undertaken in Mukono district, border-
ing Lake Victoria in Central Uganda. The district area is 
endemic for malaria, with high disease prevalence around 
May–June and November–December. The district popu-
lation is estimated at 565,700 with an annual growth rate 
of 2.3 % [16]. Most people, 88 %, live in the rural areas; 
access to ANC (at least one visit) is high, 94.1 %; however, 
only 26.7 % of pregnant women receive the two or more 
doses of SP as recommended by policy [4].
A survey was conducted from August to October 2014. 
A list of all parishes from which sampling was done was 
obtained from Uganda Bureau of Statistics, Kampala. 
The criteria for selecting study parishes were: (i) con-
tained more than 200 households to ensure a sufficient 
number of patients visiting the facilities; (ii) contained a 
health centre II, the lowest public health facility where 
early treatment and referral is sought; and (iii) contained 
at least one registered drug shop, pharmacy or private 
clinic. In total, 57 parishes with 242 private facilities were 
selected to implement the study A structured question-
naire was used to collect data targeting one provider who 
was found on duty in each selected private health facility.
Both the facility and its health workers were assessed 
using a semi-structured questionnaire. One staff in each 
private facility (drug shops, private clinics and phar-
macies) and higher level (Health Centre II, III, IV and 
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hospitals) that consented to the study was interviewed. 
In higher referral facilities the study targeted in-charges 
or deputies in the higher level facilities and whoever was 
present on the day of the interview.
The study outcome was the proportion of private health 
facilities who prescribe treatment of fever among preg-
nant women as recommended in the guidelines (quinine, 
10 m/kg in the first trimester; and ACT in the second and 
third trimester [3]).
Data collection methods
Data was captured on the following variables: provider 
characteristics, previous training received, type of drugs 
stocked, knowledge on treatment and prevention of 
malaria in pregnancy. The interviews were conducted 
by experienced research assistants, who underwent 
refresher training for 5 days on research techniques, and 
study procedures; and participated in the pretesting and 
revision of the questionnaire tools before actual field 
work. Since all private providers had a working knowl-
edge of English, the questionnaires were administered 
in English language. All aspects of data collection were 
supervised.
Sample size calculation
Sample size calculation was based on the proportion of 
private health facilities prescribing treatment of fever 
among pregnant women as recommended in the guide-
lines (quinine, 10  m/kg in the first trimester; and ACT 
in the second and third trimester) estimated at 25 %. In 
order to estimate the proportion with a  ±7  % absolute 
precision, at a power of 80 and 5 % level of significance 
(two-sided), a minimum of 232 private health facilities 
were required.
Statistical methods
Data was entered using Microsoft Access 2007 (Micro-
soft Inc., Redmond, Washington) and analysed using 
STATA version 11.0 (STATA Corporation, College Sta-
tion, Texas). Proportions on key variables were calcu-
lated using univariate analyses; factors associated with 
treatment of fever among pregnant women were assessed 
using bivariate analyses. Variables with a p value  <0.05 
were included in a logistic regression model that assessed 
factors associated with correct treatment of fever among 
pregnant women. The robustness of the regression model 
was tested using a Hosmer–Lemeshow goodness of fit 
Chi Square test and considered significant at a P >0.05.
Ethics
Ethical approval for the research was granted from 
review boards at the Uganda National Council of Sci-
ence and Technology (Ref: ss 3529). Written informed 
consent was sought prior to the interviews. The collected 
data could only be accessed by the researchers to ensure 
confidentiality.
Results
Characteristics of private health facilities
A total of 241 private health care facilities were sur-
veyed; 70.5 % were drug shops; 24.5 % were private clin-
ics and 5.0 % were pharmacies. The majority, >73 % were 
registered; and most (>75  %) were registered with the 
National Drug Authority; others were registered at the 
district level.
All the facilities sold anti-malarial drugs (Table  1). 
Almost all were stocked with artemisinin-based combi-
nations (artemether-lumefantrine), the first-line anti-
malarial drug and the majority, 82 % were stocked with 
quinine (the second-line anti-malarial drug). The major-
ity, over 78  % also stocked SP. However, a sizeable pro-
portion also stocked other anti-malarial monotherapies 
which are no longer recommended: such as chloroquine, 
12.4  % at drug shops and amodiaquine (Camoquine®, 
10.2 % at private clinics). Most of the facilities were busi-
est in the morning and evenings. The majority of private 
clinics (84.8 %) had patient registers; but only a few of the 
drug shops had a patient register, 21.2 %. Few of the pri-
vate clinics, 25  % or drug shops, 16  % had stock cards. 
RDTs were available for malaria diagnosis in more than 
75 % of pharmacies and private clinics, and in 43.8 % of 
registered drug shops. In contrast, only 44  % of private 
clinics, 42 % of pharmacies and 18 % of drug shops were 
equipped with the current national malaria treatment 
guidelines.
Provider characteristics
Providers were predominantly female, especially in drug 
shops, 87.7 % compared to 56.0 % in private clinics and 
58.3  % in pharmacies (Table  2). Similarly, the majority 
of providers at drug shops 52.9  % had not progressed 
beyond secondary education while at private clinics and 
pharmacies, the majority had attained tertiary education. 
Most providers at drug shops were of lower professional 
cadre (nursing assistants, nursing aides, enrolled nurses/
midwives); while at private clinics providers were of a 
higher professional cadre (registered nurses/midwives 
and clinical officers).
Treatment and prevention of febrile illnesses in pregnancy
Private providers were asked what treatment they give 
to pregnant women who present with fever to their 
facilities. Treatment of pregnant women with fever 
according to the guidelines was 40.7  % at private clin-
ics, 28.2  % at drug shops and 16.7  % at pharmacies. A 
big proportion, 45.9  % of drug shops prescribed SP as 
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first-line treatment for malaria to pregnant women; 
while 2.9  % prescribed ACT. The majority of provid-
ers (>75  %) at all private facilities prescribed SP for 
intermittent preventive treatment (IPTp) but arte-
misinin-based combination therapy (ACT) was also 
prescribed: 8.3, 6.9 and 8.3 % respectively at drug shops, 
Table 1 Characteristics of private health care facilities
Characteristics Registered drug shops  
N = 170
Private clinics  
N = 59
Pharmacy 
N = 12
Type of facility 170 (70.5 %) 59 (24.5) 12 (5.0 %)
Facility location 130 (76.5 %) 53 (89.8 %) 11 (91.7 %)
Urban rural 40 (23.5 %) 6 (10.2 %) 1 (8.3 %)
Facilities registered 125 (73.5 %) 54 (91.5 %) 12 (100 %)
Where facilities are registered
 District (receipt seen) 29 (23.6 %) 8 (14.9 %) 0 (0.0 %)
 NDA (license seen) 93 (75.6 %) 45 (83.3 %) 12 (100 %)
 No response 1 (0.9 %) 1 (1.9 %) 0 (0.0 %)
Busiest time at this facility
 Morning (up to 12 pm) 46 (27.1 %) 25 (42.4 %) 9 (75.0 %)
 Afternoon (12–5 pm) 10 (5.9 %) 7 (11.9 %) 0 (0.0 %)
 Evening (5–7 pm) 19 (46.5 %) 17 (28.8) 1 (8.3 %)
 Night (7–12 am) 20 (11.8 %) 5 (8.5 %) 2 (16.7 %)
 Facilities with a patient register 36 (21.2 %) 50 (84.8 %) 7 (58.3 %)
 Facilities with stock control cards 27 (15.9) 15 (25.4) 7 (58.3)
 Facilities with malaria treatment guidelines 30 (17.9) 26 (44.1) 5 (41.7)
 Facilities with a thermometer 160 (94.1) 58 (98.3) 11 (91.7)
 Facilities with an RDT for malaria diagnosis 74 (43.8) 54 (89.8) 9 (75.0)
 Facilities selling anti-malarial drugs 170 (100) 59 (100) 7 (100)
 Chloroquine 21 (12.4) 4 (6.8) 5 (41.7)
 Fansidar (SP) 134 (78.8) 52 (88.1) 12 (100)
 Camoquin 11 (6.5) 6 (10.2) 1 (8.3)
 Quinine 141 (82.9) 53 (89.8) 11 (91.7)
 ACT 166 (97.7) 57 (96.6) 12 (100)
Table 2 Providers characteristics at private health care facilities
Providers characteristics Registered drug shops  
N = 170
Private clinics  
N = 59
Pharmacy 
N = 12
Sex
 Male 21 (12.3) 26 (44.0) 5 (41.7)
 Female 149 (87.7) 33 (56.0) 7 (58.3)
Education
 Secondary 90 (52.9) 12 (20.3) 0 (0.0)
 Tertiary 80 (47.1) 43 (72.9 %) 10 (83.3)
 University 0 (0.0) 4 (6.8) 2 (16.7 %)
Level of professional training
 Nursing aide 11 (6.5) 0 (0.0) 11 (4.6)
 Nursing assistant 82 (48.2) 6 (10.2) 2 (16.7)
 Enrolled nurse/midwife 52 (30.6) 6 (10.2) 2 (16.7)
 Registered nurse/midwife 6 (3.5) 7 (11.9) 0 (0.0)
 Clinical officer 4 (2.4) 14 (23.7) 2 (16.7)
 Doctor 0 (0.0) 3 (5.1) 0 (0.0)
Page 5 of 7Mbonye et al. Malar J  (2016) 15:212 
private clinics and pharmacies for prevention of malaria 
in pregnancy.
Knowledge on pregnant women being vulnerable to 
malaria was low, 11.2  % at drug shops, 6.8  % at private 
clinics and none at pharmacies. Most providers,  >89  % 
recommended ITNs to pregnant women for malaria pre-
vention (Table 3). The following factors were associated 
with correct treatment given to pregnant women with 
fever: the type of facility (drug shop), P = 0.04; knowledge 
of people vulnerable to malaria, P = 0.02; and availability 
of a malaria treatment guideline, P = 0.03 (Table 3).
Discussion
The present results show that treatment of pregnant 
women with fever according to national guidelines was 
poor in a substantial number of private health facili-
ties, with less than 40  % of providers in private clinics, 
registered drug shops and pharmacies in rural Uganda 
knowing the correct first-line treatment for malaria dur-
ing pregnancy. It is further shown that while majority of 
providers at private facilities correctly prescribed SP for 
IPTp, some drug shops also prescribed ACT and quinine 
for prevention of malaria in pregnancy. These results are 
Table 3 Level of knowledge, treatment and prevention of malaria in pregnancy at private health facilities
Knowledge, treatment and prevention of malaria in pregnancy Registered drug shops  
N = 170
Private clinics  
N = 59
Pharmacy 
N = 12
Knowledge about of people at risk of malaria
 All people 24 (14.1) 10 (17.0) 9 (41.7)
 Children (0–5) 58 (43.1) 30 (50.9) 5 (41.7)
 Children (6–15) 61 (35.9) 10 (17.0) 1 (8.3)
 Adults 8 (4.7) 4 (6.8) 0 (0.0)
 Pregnant women 19 (11.2) 4 (6.8) 0 (0.0)
Treatment given to pregnant women with fever according to the guideline
 First trimester give quinine and second trimester give (ACT) as recom-
mended by the guideline
48 (28.2) 24 (40.7) 2 (16.7)
Drugs given to pregnant women who present with fever
 ACT 5 (2.9) 4 (6.8) 1 (8.3)
 SP 78 (45.9) 11 (18.6) 3 (25.0)
 Quinine 12 (7.1) 7 (11.9) 2 (16.7)
 Paracetamol 12 (7.1) 4 (6.8) 2 (16.7)
 Other (amoxicillin, folic acid, iron) 15 (8.8) 9 (15.3) 2 (16.7)
Anti-malarial drug given to for malaria prevention
 Quinine 5 (3.0) 0 (0.0) 1 (8.3)
 ACT 14 (8.3) 4 (6.9) 1 (8.3)
 SP 128 (76.2) 52 (89.2) 9 (75.0)
 Other (amoxicillin, chloroquine, vitamin B-complex) 21 (12.5) 2 (3.5) 1 (8.3)
Malaria prevention interventions providers recommend to pregnant women
 Insecticide treated nets (ITNs) 152 (91.0) 52 (89.7) 12 (100)
 In-door residual spray (IRS) 2 (2.4) 2 (3.5) 0 (0.0)
 Advice on good nutrition 3 (1.8) 2 (3.5) 0 (0.0)
 Close windows early 3 (1.8) 1 (1.7) 0 (0.0)
Factors associated with treatment (according to guideline) given to pregnant women with fever Statistical significance
Drug shop P = 0.04
Private clinic P = 0.10
Availability of malaria treatment guideline P = 0.03
Presence of a functional laboratory P = 0.90
Presence of a functional microscope P = 0.80
Knowledge of people vulnerable to malaria P = 0.02
Professional qualification of the provider P = 0.70
Having attended a course on malaria management P = 0.80
Having an RDT P = 0.04
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compounded by low knowledge that pregnant women are 
at increased risk of malaria. These results have implica-
tions for the safety of pregnant women visiting private 
health facilities. Of immediate importance for the Min-
istry of Health is the need to design messages to cre-
ate awareness that pregnant women are vulnerable to 
malaria and to distribute the most updated malaria treat-
ment and prevention guideline to private health facilities.
It is shown that less than half of drug shops had rapid 
diagnostic tests (RDTs) (Table  3). There is potential to 
scale up use of RDTs in these outlets based on recent find-
ings that showed high adherence to RDT test results and 
improved appropriate treatment of malaria with ACT in 
drug shops [17]. Nevertheless, in the private sector where 
RDTs exist, further operational research will be required to 
monitor adherence to RDT test results, treatment of non-
malaria febrile illnesses and referral practices over time. It 
is shown that facilities which had RDTs were more likely to 
treat pregnant women with fever appropriately. This find-
ing justifies the need to scale up this diagnostic tool.
Similar results have been documented in Nigeria where 
there was little knowledge about treatment and chemo-
prophylaxis for malaria in pregnancy especially in the 
private sector; and many providers could not recognize 
maternal and neonatal deaths as potential consequences 
of malaria in pregnancy [20]. In Zambia, although not 
among pregnant women, approximately 30 % of patients 
who were found negative for malaria parasites were pre-
scribed an anti-malarial drug contrary to the national 
guidelines [21]. It was further shown that malaria case 
management was characterized by poor adherence to 
treatment guidelines, mainly due to inconsistent use of 
confirmatory tests (rapid diagnostic test or microscopy); 
prescribing anti-malarial drugs which were not recom-
mended (e.g. sulfadoxine-pyrimethamine) and prescrib-
ing anti-malarial drugs to cases testing negative [21].
Although the present results have highlighted deficien-
cies in treatment practices for fever in pregnancy and the 
need for improved policy guidance for providers in the 
private sector; similar concerns might also be raised in 
the public sector. A recent review showed that no coun-
try in sub-Saharan Africa provides appropriate guidance 
on management of uncomplicated and severe malaria 
during pregnancy [22]. In all countries, inconsistencies 
between National Malaria Control programmes and 
Reproductive Health programmes on the timing or dose 
of IPTp-SP were documented, as was the mechanism 
for providing long-term insecticide-treated nets. Incon-
sistencies were also found in training documents from 
both programmes. It was concluded that out-dated and 
inconsistent guidelines had the potential to cause confu-
sion and lead to incorrect practices among health work-
ers who implement malaria in pregnancy programmes, 
contributing to low coverage of IPTp-SP and long-lasting 
insecticidal nets (LLINs) [22, 23].
Use and safety of drugs in pregnancy is a major concern. 
A study has recently shown that trimethoprim is a poten-
tial teratogen when used 3 months before pregnancy [24]. 
It has also been found that Mefloquine as IPTp is not 
well tolerated, limiting its potential for IPTp and indicat-
ing the need to find alternatives with better tolerability to 
reduce malaria in this particularly vulnerable group [25]. 
Accordingly, the World Health Organization (WHO) rec-
ommends artemisinin-based combination therapy (ACT) 
to treat uncomplicated falciparum malaria during the sec-
ond and third trimesters of pregnancy, and quinine plus 
clindamycin during the first trimester [26]. However, the 
national policies of many African countries currently rec-
ommend quinine throughout pregnancy. Although there 
are few reports of AL safety in the first trimester addi-
tional data are required to assess the potential to use AL 
in the first trimester [26, 27].
The immediate policy implications of these findings 
is to distribute the most updated malaria treatment and 
prevention guideline to private health facilities and to 
discuss with the Ministry of Health, district leaders, 
the national drug authority (NDA) and the professional 
councils that register private providers in Uganda to 
design continuing medical education (CME) and super-
vision modalities to ensure quality and safety of patients 
seeking care at these facilities. It is recommended that 
further studies to compare the effectiveness and cost of 
different supervision modalities for the private facilities 
and how best to link them to the public health system be 
conducted. Although interventions to improve quality of 
care in the private sector are recommended, there is cau-
tion that pregnant women may miss out on a wider ANC 
package like HIV testing and access to anti-retroviral 
therapy (ART) that may exist in the public sector. Thus a 
clear guideline is required on referral of pregnant women 
to ANC for other essential maternity care.
A limitation of this study is that treatment practices were 
never observed when pregnant women visited the facili-
ties; neither was it possible to document what questions 
women asked when they visited the facilities. This how-
ever required an in-depth study that was beyond the scope 
of this study in terms of time and funds and exploration 
of these in further research is recommended. Nonethe-
less, the survey covered a large number of private health 
facilities and the treatment and prevention practices docu-
mented could be generalized to most parts of Uganda.
In conclusion, the study presents disturbing results 
that show poor treatment and prevention of malaria in 
pregnancy at private health facilities. Interventions to 
increase access to effective treatment and prevention of 
malaria in pregnancy in this sector are urgently needed.
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